- Open Access
Peripheral mechanisms of neuropathic pain – involvement of lysophosphatidic acid receptor-mediated demyelination
Molecular Painvolume 4, Article number: 11 (2008)
Recent advances in pain research provide a clear picture for the molecular mechanisms of acute pain; substantial information concerning plasticity that occurs during neuropathic pain has also become available. The peripheral mechanisms responsible for neuropathic pain are found in the altered gene/protein expression of primary sensory neurons. With damage to peripheral sensory fibers, a variety of changes in pain-related gene expression take place in dorsal root ganglion neurons. These changes, or plasticity, might underlie unique neuropathic pain-specific phenotype modifications – decreased unmyelinated-fiber functions, but increased myelinated A-fiber functions. Another characteristic change is observed in allodynia, the functional change of tactile to nociceptive perception. Throughout a series of studies, using novel nociceptive tests to characterize sensory-fiber or pain modality-specific nociceptive behaviors, it was demonstrated that communication between innocuous and noxious sensory fibers might play a role in allodynia mechanisms. Because neuropathic pain in peripheral and central demyelinating diseases develops as a result of aberrant myelination in experimental animals, demyelination seems to be a key mechanism of plasticity in neuropathic pain. More recently, we discovered that lysophosphatidic acid receptor activation initiates neuropathic pain, as well as possible peripheral mechanims of demyelination after nerve injury. These results lead to further hypotheses of physical communication between innocuous Aβ- and noxious C- or Aδ-fibers to influence the molecular mechanisms of allodynia.
Chronic pain should be considered to be a disease rather than just a symptom, because it is one of most common reasons for hospital visits. Although recent advances in molecular biology techniques, and the subsequent discoveries of key molecules involved in pain production, have clearly contributed to better understanding acute pain [1–4], the molecular mechanisms underlying chronic pain remain to be fully clarified.
Chronic pain, or specifically neuropathic pain, is quite different from other types of pain, such as nociceptive (or physiological) or inflammatory pain, because it is irreversible, even when the underlying cause has been rectified . For this reason, the proper diagnosis and early treatment are often difficult. Moreover, neuropathic pain commonly occurs as a secondary symptom in diseases, such as diabetes, cancer, and herpes zoster infection, or as a side effect of chemotherapeutic treatments [3, 5–7]. Neuropathic pain is often characterized by stimulus-independent persistent pain or abnormal sensory perception of pain, such as allodynia (pain perception upon the innocuous tactile stimuli) and hyperalgesia (exaggerated pain sensations by mildly noxious stimuli) [3, 8]. To treat chronic pain, we must first understand the initial and sustained molecular events in experimental animal models. Because the central mechanisms of sustained molecular events, which are closely related to memory in the brain, have been described in elsewhere in detail [9, 10], this review focuses on peripheral mechanisms of initial events from nociceptors to the spinal dorsal horn.
Approaches to study plasticity in nociceptor endings
Neuropathic pain occurs as a consequence of complex sensory dysfunction and may differ depending on the type of insult and the individual patient. Furthermore, due to the dynamic nature of the pain system, signs and symptoms of neuropathic pain change over time. Injury to peripheral nerves causes functional and biochemical changes at the site of injury, as well as to other areas of the affected nerve, and later to higher order neurons in the spinal cord and brain [3, 8–12]. Nociceptor endings cause a generator potential, which leads to an action potential in polymodal C and mechanothermal Aδ fibers [1, 13]. These action potentials are then conducted to higher centers in the central nervous system (CNS) via neurotransmitter release and are accompanied by a variety of responses, including withdrawal reflexes, conscious perception of pain, and emotional effects. The pain signal, on the other hand, drives the descending noradrenergic and serotonergic pain-inhibitory systems from the lower brain stem to the spinal dorsal horn . Therefore, chronic neuropathic pain is a result of problems in ascending pain transmission or descending pain-inhibitory system.
The identification of mechanisms or key molecules related to hyperalgesia and allodynia in neuropathic pain could be elucidated by studies using antisense oligos, RNA interference (RNAi), or transgenic (KO) mice lacking specific genes. However, these approaches present difficulties, such as: 1) intrathecal treatments with antisense oligo or RNAi cannot specify whether the action site is on sensory fibers or the spinal cord, although some studies have demonstrated dorsal root ganglion (DRG)-specific down-regulation [15, 16]; 2) the availability of specific KO mice is limited, and functional compensation during development and growth may modify the roles of the genes involved; and 3) the availability of conditional KO mice is even more limited. Considering this, as an initial attempt to survey key molecules responsible for neuropathic pain, we have developed novel nociception tests to measure algogenic-induced paw flexion (APF) .
Pharmacological plasticity in neuropathic hyperalgesia
Our laboratory has developed a highly sensitive and minimally stressful nociception test (APF test) in mice . In this test, the mouse is held in a hammock-type cloth sling, which is suspended from a bar, and nociceptive responses (in force) that are induced by intraplantar injection of a receptor ligand or algogenic substance can be measured. The APF test has proven to be advantageous for the study of in vivo pain signal transduction at peripheral nerve endings and has enabled the characterization of pain induction through nociceptors on C- or Aδ-fibers. In vivo signal transduction can be studied through the use of pharmacological methods using intraplantar treatments with various inhibitors and intrathecal pretreatments with antisense oligodeoxynucleotide (AS-ODN). The AS-ODN treatments are intended to determine whether the action site of compounds (i.pl.) reside on nociceptor endings or on non-neuronal peripheral cells.
Pharmacological studies have shown that the nociceptive fibers are responsible for various algogenics actions, which can be divided into three groups . Neonatal pretreatment of capsaicin degenerates unmyelinated C fibers, polymodal nociceptive fibers [18–20]. Spinal antagonism, using receptor antagonists for substance P (SP) or glutamate, is another way to characterize nociceptive fibers. The use of neonatal capsaicin-sensitivity and spinal antagonism enabled us to pharmacologically categorize algogenic-induced nociceptive flexor responses into three groups : 1) subcutaneous (s.c.) capsaicin-pretreatment and/or intrathecal (i.t.) pretreatment with NK1-type SP receptor antagonist abolished nociceptive responses to bradykinin (BK), SP, and histamine (His), which are representative chemical mediators; 2) ATP-induced responses were abolished with pretreatments of neonatal capsaicin (s.c.) or NMDA receptor antagonist (i.t.), but not by NK1 antagonist (i.t.); 3) PGI2 receptor agonist-induced responses were not affected by neonatal capsaicin, but were abolished by the NMDA antagonist. Therefore, we proposed that C-fibers could be further divided into two groups: peptidergic type 1 (SP-containing) and non-peptidergic type 2 (P2X3 receptor-expressing) C-fibers. This proposal is similar to the schematic model proposed by Snider & McMahon , who report two groups of C-fibers with differential gene (or protein) expression. This sub-classification of C-fibers is anatomically supported elsewhere ; only 3% of P2X3 receptor-positive neurons co-existed with SP in rat DRG neurons. Our proposal suggested a third group (type 3) of nociceptive fibers that may be related to myelinated A(δ) fibers, as opposed to C fibers .
Partial injury to peripheral nerves has been used to generate representative experimental animal models for neuropathic pain , where remarkable functional and molecular changes are observed. The injury-induced expression of Nav1.3 in large (A-fiber) DRG neurons  is thought to be one of the mechanisms underlying the hypersensitivity. We have also observed injury-induced appearance of TRPV1 and B1-type BK receptors in N52 (an A-fiber marker)-positive DRG neurons [15, 25]. Neuropeptides, such as galanin, neuropeptide Y (NPY), and pituitary adenylyl cyclase activating polypeptide (PACAP), which are normally expressed at low levels in sensory neurons, are dramatically increased in DRG neurons, including medium to large size neurons (A-fibers) [26–29]. Recently, a paper described reduced neuropathic pain in mice lacking PACAP . Nevertheless, the up-regulation of these neuropeptides is not always the mechanism intrinsic to neuropathic pain. NPY-null mice exhibit autotomy-like biting behaviors , augmentation of neuropathic pain is observed in NPY Y1 receptor-null mice , and i.t. injection of NPY inhibits neuropathic pain . Similarly, neuropathic pain is decreased in transgenic mice overexpressing galanin, and augmented in galanin receptor 1-null mice [33, 34]. On the contrary, some molecules, such as substance P [28, 35], Nav1.8, and Nav1.9, are down-regulated [36, 37]. These modifications may be generalized functional switches of C-fibers to A-fibers, as evidenced by the down-regulation of C-fiber mechanisms and the up-regulation of A-fiber mechanisms .
Sensory fiber-specific plasticity in neuropathic allodynia
Allodynia is the best target to investigate molecular mechanisms underlying neuropathic pain. In the APF test, hypoalgesia could be characterized through peptidergic C-fibers and A(δ)-hyperalgesia, another feature of neuropathic pain. This test mimics the physiological event where, upon exposure to noxious stimuli, chemicals are secreted in the vicinity of nerve endings to stimulate these nociceptive fibers. However, because the peripheral nerve terminals of innocuous Aβ fibers, which are thought to mediate allodynia, are covered by nonneuronal supporting cells, and protected from chemicals, different nociception tests are needed to characterize Aβ-fibers.
In order to characterize Aβ fiber-mediated pain transmission, we have recently developed novel nociception tests, using the Neurometer®, called electrical stimulation-induced paw flexion (EPF) and paw withdrawal (EPW) tests [7, 38]. The EPF test uses the same apparatus as the APF test; however, the EPF test utilizes electrodes placed on the plantar surface and instep, rather than a cannula filled with drug solution (Fig. 1a). In the EPW test, the mouse is hand-held and electrical stimulation is applied to the paw (Fig. 1b). Latency of paw withdrawal behavior is evaluated as the nociceptive threshold. In both the EPF and EPW tests, the threshold is consistently reproducible, even after repeated applications to the same mouse. According to the manufacturer's protocol for Neurometer®, low (LF, 5 Hz), medium (MF, 250 HZ), and high frequency (HF, 2000 Hz) electrical stimulation results in stimulation of C-, Aδ-, and Aβ-fibers, respectively [39, 40]. Through the use of electrophysiology, Koga et al.  confirmed frequency-specific stimulation of sensory fibers characterization with the Neurometer®. This specificity could be attributed to different electrical characteristics of C-, Aδ-, and Aβ-fibers. C-fibers generate a slow sodium-dependent spike due to the presence of tetrodotoxin (TTX) – resistant sodium channels, Nav1.8 and Nav1.9, which exhibit slow kinetics patterns for activation, inactivation, and recovery from inactivation or repriming, while A-fibers predominantly express TTX-sensitive channels such as Nav1.1, Nav1.6, Nav1.7, which exhibit fast kinetics patterns to allow high frequency firing [42, 43], as shown in Fig. 1c.
Matsumoto et al.  also confirmed frequency-specificity with a pharmacological study; neonatal capsaicin treatments to cause a damage of C-fibers eliminated LF-stimuli-induced nociceptive behavior, but not MF- or HF-stimuli-induced behaviors. These results suggest that nociceptive behavior from LF-stimuli is a result of C-fiber stimulation, while MF- or HF-stimuli-induced behavior is due to A-fiber stimulation. Furthermore, MF-stimulus to the finger results in sharp pain (prickly feeling), while HF-stimulus causes an unpleasant vibrating perception (light tickle).
Further pharmacological characterizations strengthened the validity of behavioral studies using Neurometer® [38, 44]. Both NK1 and NMDA receptor antagonists inhibited LF-stimuli-induced nociceptive responses; NMDA receptor antagonists inhibited MF-responses, while AMPA/kainate (non-NMDA) receptor antagonists specifically inhibited HF-induced behaviors (Fig. 1c), which is consistent with previous reports . The characteristics of pain behavior were consistent to those obtained with the measurement of neuron-specific phosphorylation of extracellular signal-regulated kinase 1/2 (p-ERK). Studies have shown that LF-stimuli induced neuronal p-ERK signals at the spinal dorsal horn (lamina I and II) were inhibited by NK1 and NMDA receptor antagonists, while MF-induced signals (lamina I) were specifically inhibited by the NMDA receptor. Moreover, HF stimuli resulted in no signal in the spinal cord. Thus, it seems likely that LF-stimuli causes C-fiber stimulation, while MF- or HF-stimuli causes nociceptive A(δ) or innocuous A(β)-fiber stimulation, respectively, in naïve animals and humans. It is unlikely that cutaneous application of high frequency (250 or 2000 Hz) electrical stimuli is capable of completely stimulating sensory fibers at the same frequency. Koga et al.  reported ~3 Hz C-fiber, ~22 Hz Aδ-fiber, and ~140 Hz Aβ-fiber responses after 5, 250, and 2000 Hz stimulation, respectively; these responses are similar to physiological levels .
Functional mechanisms influencing neuropathic allodynia
According to the previous hypothesis for neuropathic allodynia, nerve damage results in a retraction of C-fibers and allows for intrusion of A-fibers to the newly created space and loss of C-fiber pain transmission. This hypothesis was originally proposed with anatomical studies that demonstrated that nerve transection produces central sprouting of large fibers from deep laminae to lamina II [48, 49]. Although nerve injury-induced intrusion of Aβ-fibers to the superficial dorsal horn layers has not been well documented, this hypothesis received functional support through electrophysiological studies .
Behavioral studies (APF test) have determined a loss of peptidergic C-fiber responses after nerve injury [25, 35]. The down-regulation of C-fiber specific molecules, such as Nav1.8 and 1.9 [36, 37] and bradykinin B2 receptor , could be responsible for this type of neuropathic pain. The down-regulation of pain transmitter SP in the dorsal horn of spinal cord could be another mechanism [3, 35, 51]. Because SP precursor preprotachykinin (PPT)-null mice continued to exhibit neuropathic pain, the loss of peptidergic C-fiber function may not be significant stimuli to cause nociceptive behaviors. Alternatively, up-regulation of NK1 receptor expression in the spinal cord  may counteract the threshold change.
On the other hand, hypersensitization or allodynia upon innocuous stimulation has been studied. These studies demonstrated, in particular, the up-regulation of large-fiber-specific molecules [15, 24, 25, 27]. Although these changes may be responsible for neuropathic hyperalgesia, they cannot explain the mechanism of allodynia. The novel method using the Neurometer® clearly demonstrates Aβ-fiber stimulation-induced nociceptive flexor responses . Following partial sciatic nerve injury, LF-stimuli-induced behavioral responses were significantly inhibited in the EPF test, while MF-stimuli-induced responses were enhanced . These results are in accordance with studies using the APF test to determine that peptidergic C-fiber responses were lost, while Aδ-fiber responses were hypersensitized . It should be noted that similar injury-specific hypersensitization was also observed with HF-stimuli [38, 44], which should stimulate innocuous fibers in naïve mice. Consistent results were also observed when neuronal p-ERK signals were measured at the spinal dorsal horn . Most interestingly, HF-stimuli generated significant p-ERK signals at the spinal cord lamina I and II after nerve injury. Pharmacological characterization after the injury also verified the plasticity that HF-stimuli (Aβ)-induced spinal transmission is mediated by NMDA receptor, but not by non-NMDA receptor [44, 46].
Thus, functional changes following nerve injury suggest that two molecular events are taking place: communication between different sensory fibers and C-fiber retraction. Demyelination, and subsequent physical cross-talk, might be the mechanism responsible for neuropathic pain, because many demyelinating diseases accompany chronic pain, as with Guillain-Barre syndrome , Charcot-Marie-Tooth type I disease , and multiple sclerosis . Indeed, it has been reported that neuropathic pain develops as a result of aberrant myelination (splitting, detachment, and loss of myelin) in mice deficient in the myelin protein periaxin . However, little is known of the molecular events causing demyelination in the diseases that accompany neuropathic pain.
Lysophosphatidic acid (LPA) mimics nerve injury-induced neuropathic pain
A number of pharmacological studies suggest that lysophosphatidic acid (LPA) might cause neuropathic pain and demyelination following partial sciatic nerve injury. LPA is one of several lipid metabolites released after tissue injury, as well as from various cancer cells [57–59]. LPA receptors activate multiple signaling pathways and multiple G-proteins [60–64]. Direct stimulation of peripheral nociceptor endings by LPA, through LPA1 receptors, also suggests a role in nociceptive processes [65, 66]. Of particular note, receptor-mediated LPA signaling via Gα12/13 activates the small GTPase RhoA [63, 64, 67]. In the active state, Rho is translocated to the plasma membrane and thereby relays extracellular signals to multiple downstream effectors, including Rho-kinase or ROCK, which can be inhibited by the pyridine derivative compound, Y-27632. Inhibition of the Rho pathway can also be accomplished by selective ADP-ribosylation of RhoA, using Clostridium botulinum C3 exoenzyme (BoTN/C3). The involvement of Rho-ROCK system in neuropathic pain mechanisms was initially demonstrated by i.t. injections of BoTN/C3 prior to peripheral nerve injury in mice, which blocked the development of hyperalgesia . LPA receptors and LPA receptor gene expression activates Rho in peripheral nerves [69–71], which suggests that LPA receptors might pathophysiologically activate Rho in neuropathic pain states of peripheral nerve injury. An interesting study illustrated that LPA inhibits the filopodia of growth cones . LPA could be involved in C-fiber retraction, which is a hypothesis supporting functional changes induced by neuropathic pain. Together, these findings present LPA as an attractive signaling molecule in the development of neuropathic pain.
Indeed, a single i.t. injection of LPA produced marked mechanical allodynia and thermal hyperalgesia that persisted for at least 7–8 days before returning to baseline levels at day 13 . Sphingosine 1-phosphate (S1P), which signals through S1P receptors and shares similar signaling pathways with LPA receptors , did not produce mechanical allodynia after i.t. injections in mice. These findings, therefore, highlight the specificity of LPA. Further studies have shown that LPA-induced thermal hyperalgesia and mechanical allodynia could be blocked by BoTN/C3 (i.t.) and Y-27632 . In addition, LPA decreased the peptidergic , but not non-peptidergic C-fiber responses, but markedly increased A(δ)-fiber responses in the APF test, which strongly suggests that LPA mimics partial sciatic nerve injury by causing neuropathic pain .
Ex vivo studies of LPA-mediated demyelination
Consistent with the fact that receptor-mediated LPA signaling influences the morphology of Schwann cells , the i.t. injection of LPA (1 nmol), as well as partial sciatic nerve injury, caused demyelination of the dorsal root within 24 h; this demyelination was abolished by pretreating with BoTN/C3 . An ex vivo study using dorsal root fibers also demonstrated that the addition of LPA causes demyelination of A-fibers and damage to Schwann cells, which promotes direct contact between C fibers in the Remak bundle  (Fig. 2). LPA-induced demyelination was, however, reversed by BoTN/C3 or Y27632, a ROCK inhibitor. In addition, myelin basic protein (MBP) and myelin protein zero (MP0) were down-regulated. LPA-injection (i.t.) or partial sciatic nerve injury in mice produced demyelination in the dorsal root, but not in the spinal nerve, although the addition of LPA led to significant demyelination in both fibers ex vivo, which suggests that in vivo demyelination occurs specifically at the dorsal-root, proximal to the spinal cord. Furthermore, we observed that simultaneous ligation of the residual half of the sciatic nerve triggered only a slight increase in demyelination. Taken together, these findings provide speculation to the theory that certain spinal cord-originating extracellular signaling molecules, including LPA, diffuse to the dorsal root to cause demyelination.
Involvement of LPA1-signaling in nerve injury-induced neuropathic pain
LPA acts through G-protein-coupled LPA receptors, designated LPA1, LPA2, LPA3, and LPA4, each exhibiting different G protein interactions [63, 64]. However, only the lpa1 receptor gene is expressed in both DRG neurons and dorsal root . LPA1-null mice reversed LPA-induced demyelination, as well as mechanical allodynia . Furthermore, LPA1 receptor-mediated demyelination was evidenced by down-regulation of myelin-associated proteins, such as MBP and peripheral myelin protein 22 kDa (PMP22), in the dorsal root after LPA injection or peripheral nerve injury. These changes were identical to nerve injury changes resulting in neuropathic pain. Indeed, LPA1-null, reversed nerve injury-induced neuropathic pain and demyelination, as well down-regulation of myelin proteins and up-regulation of A-fiber Cavα2δ-1 and spinal PKCγ .
Nerve injury-induced de novo LPA biosynthesis
It is important to understand whether endogenous LPA plays a role in the development of neuropathic pain; if so, it will be important to demonstrate the mechanisms involved. Thermal hyperalgesia and mechanical allodynia after partial sciatic nerve ligation were mostly reversed by pretreatment with AS-ODN for LPA1 or in LPA1-null mice . Because no significant nociceptive threshold change was observed in uninjured LPA1-null mice, it is evident that de novo LPA, produced by injury, is involved in the generation of a neuropathic pain state. Similar roles of de novo-produced LPA have also been observed in demyelination, decreased protein and gene expression of related myelin molecules (MBP and PMP22), and upregulation of PKCγ and of Cavα2δ-1 in mice with partial sciatic nerve ligation . Furthermore, LPA1 receptor-mediated demyelination was specific to the dorsal root after the sciatic nerve injury. Taken together, these findings suggest that LPA is biosynthesized de novo in the spinal cord upon intense pain signals, and is subsequently released at the dorsal root to cause demyelination. Autotaxin (or lysophospholipase D), which converts lysophosphatidyl choline (LPC) to LPA, is a key enzyme for LPA production . Recent studies revealed that phosphatidyl choline is converted to LPC by cytosolic phospholipase A2 (cPLA2) or calcium-independent PLA2 (iPLA2), both of which are regulated by Ca2+-related mechanisms. cPLA2 is activated through membrane translocation, which is stimulated by Ca2+ or phosphorylation by mitogen-activated kinase (MAPK) or PKCs [76–78], while iPLA2 is activated through the removal of calmodulin by calcium influx factor (CIF) produced after Ca2+ depletion in the endoplasmic reticulum [79, 80]. Therefore, intense pain-signals after nerve-injury may induce an excess release of pain transmitters, SP, and glutamate, which in turn activate both cPLA2 and iPLA2 through different pathways (Fig. 3). Neurotrophic factors (e.g., BDNF) and cytokines may also contribute to cPLA2 activation through MAPK-activating pathways. More recently, neuropathic pain was shown to be induced by LPC (i.t.) or nerve injury and was absent in LPA1-null or autotaxin-null mice [81, 82]. Our recent findings showed that LPC did not cause demyelination in ex vivo experiments, although many reports have demonstrated LPC-induced demyelination in vivo [83–85]. Taken together, these findings might suggest that de novo-produced LPC in the spinal cord is transported to the dorsal root, where it is then converted to LPA.
LPA as an initiator of nerve-injury-induced neuropathic pain
Neuropathic pain behavior at day 14 was absent after pretreatment with AS-ODN for LPA1, but not with later treatments that started at day 7 post-injury . Neuropathic pain was also blocked when BoTN/C3 was administered within 1 h post-injury. A time-course study using Ki-16425, a short-lived LPA1 antagonist  revealed that LPA1 receptor signaling was found to terminate within 3 h following injury (Lin and Ueda et al., unpublished data). These findings suggest that de novo-produced LPA after nerve injury might initiate various mechanisms of neuropathic pain through the LPA1 receptor .
Working hypothesis for LPA1 signaling initiating neuropathic pain
LPA1 receptor-mediated demyelination is an important subject in the field of neuropathic pain. We obtained evidence that LPA1 receptor activation mediates down-regulation of myelin proteins, such as peripheral myelin protein PMP22, myelin basic protein MBP, and myelin protein zero MP0, in in vivo injury models and ex vivo culture models [73, 74]. Nerve injury-induced down-regulation of myelin proteins and their genes was reversed with BoTN/C3 pretreatment; however, further downstream mechanisms remain to be determined. Because the time-course of down-regulated protein levels is similar to the gene expression , the former mechanism seems to be a result of rapid degradation, and not a secondary event subsequent to the down-regulation of gene expression. It should be noted that myelin-associated glycoprotein (MAG) was also down-regulated, while growth associated protein 43, a marker protein for sprouting axonal growth, was up-regulated (Fujita, Ueda et al., unpublished data). This is consistent with the fact that MAG inhibits axonal growth through activation of the NOGO/p75 receptor complex and leads to inhibition of actin polymerization mechanisms [87–89] (Fig. 4). Thus, it is interesting to speculate that these mechanisms are responsible for ephaptic or physical crosstalk between different modalities of fibers through sprouted A-fiber branches.
In patients and experimental animals with neuropathic pain, mild tactile stimulation causes burning pain. This phenomenon, termed allodynia, has been the focus in our study of neuropathic pain mechanisms. The possibility that tactile Aβ and nociceptive Aδ or C fibers cross at the level of sensory fibers, or at the level of pain transmission in the spinal dorsal horn, would seem to be a reasonable explanation . Collateral sproutings from primary afferent fibers, which induces ephaptic or physical crosstalk between different types of fibers, have long been speculated to be involved in the plasticity or reorganization mechanisms of spinal neuronal circuits for pain transmission . Evidence of LPA-induced demyelination accompanying loss of insulation could account for the physical crosstalk (presumed structural basis of ephaptic crosstalk) between non-nociceptive (Aβ) and nociceptive (C and Aδ) fibers, which is observed in mice with nerve injury (Fig. 5). On the other hand, subsequent to peripheral nerve injury, the regenerating axon terminals are known to sprout to the skin area that is typically denervated . Local NGF release from skin cells is expected to drive this sprouting, because anti-NGF treatment prevents sprouting . Further studies focused on growth factor-induced sprouting after LPA activation are needed. Altogether, we propose a hypothesis for mechanisms of neuropathic hyperalgesia and allodynia after partial sciatic nerve injury (Fig. 6) as follows: 1) intense stimulation of sensory neurons after sciatic nerve injury activates target neurons in the dorsal horn to induce de novo biosynthesis of LPC, which is in turn converted to LPA by ATX/LPLD; 2) LPA is then produced at the dorsal root fibers proximal to the spinal cord. LPC may be also produced at the dorsal root, where it is converted to LPA; 3) LPA binds to LPA1 receptors, resulting in retraction of peptidergic unmyelinated C-fibers. The C-fibers are deprived of spinal pain transmission, due to down-regulation of various pain-related molecules (B2-type BK receptor on fibers, SP level in the dorsal horn), as well as the possible retraction of central nerve endings; 4) myelinated Aδ-fibers exhibit hypersensitivity due to up-regulation of TRPV1, B1-type BK receptor, and Cavα2δ-1. However, it remains to be shown that the LPA1 receptor is involved in expression changes of key molecules. It also remains to be determined whether LPA1 receptor signaling directly causes the down-regulation of these molecules; 5) LPA, which is released at the dorsal root, demyelinates the Aδ- and Aβ-fibers on the dorsal root through the LPA1 receptor, followed by physical (or ephaptic) crosstalk between the C-fiber and Aδ-fiber, and between the Aδ-fiber and Aβ-fiber. Sprouting also causes novel pain transmission in the spinal dorsal horn. These two events following demyelination may regulate the mechanisms of neuropathic allodynia.
Neuropathic pain is thought to become worse with time, if not appropriately treated. This present review proposes initial mechanisms at the level of peripheral nerves following nerve injury. The development of agents to block enhanced pain transmission is an important therapeutic direction for research. It would be important to target the crosstalk between noxious and innocuous fibers after demyelination to cure or prevent neuropathic pain. Sustained mechanisms could occur at the spinal and supraspinal levels. Plasticity or reorganization of neural networks in pain and pain-inhibitory pathways could make treatment more problematic. Pain induces pain in a vicious circle. Complete blockade of the plasticity responsible for neuropathic pain at the initial stage and at the peripheral level might be an appropriate strategy.
Woolf CJ, Ma Q: Nociceptors--noxious stimulus detectors. Neuron 2007, 55: 353–364. 10.1016/j.neuron.2007.07.016
Scholz J, Woolf CJ: Can we conquer pain? Nat Neurosci 2002, 5 Suppl: 1062–1067. 10.1038/nn942
Ueda H: Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006, 109: 57–77. 10.1016/j.pharmthera.2005.06.003
Hucho T, Levine JD: Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55: 365–376. 10.1016/j.neuron.2007.07.008
Campbell JN, Meyer RA: Mechanisms of neuropathic pain. Neuron 2006, 52: 77–92. 10.1016/j.neuron.2006.09.021
Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353: 1959–1964. 10.1016/S0140-6736(99)01307-0
Matsumoto M, Inoue M, Hald A, Xie W, Ueda H: Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin. J Pharmacol Exp Ther 2006, 318: 735–740. 10.1124/jpet.106.103614
Bridges D, Thompson SW, Rice AS: Mechanisms of neuropathic pain. Br J Anaesth 2001, 87: 12–26. 10.1093/bja/87.1.12
Zhuo M: Neuronal mechanism for neuropathic pain. Mol Pain 2007, 3: 14. 10.1186/1744-8069-3-14
Tracey I, Mantyh PW: The cerebral signature for pain perception and its modulation. Neuron 2007, 55: 377–391. 10.1016/j.neuron.2007.07.012
Sandkuhler J: Understanding LTP in pain pathways. Mol Pain 2007, 3: 9. 10.1186/1744-8069-3-9
Vanegas H, Schaible HG: Descending control of persistent pain: inhibitory or facilitatory? Brain Res Brain Res Rev 2004, 46: 295–309. 10.1016/j.brainresrev.2004.07.004
Baron R: Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol 2006, 2: 95–106. 10.1038/ncpneuro0113
Yoshimura M, Furue H: Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci 2006, 101: 107–117. 10.1254/jphs.CRJ06008X
Rashid MH, Inoue M, Matsumoto M, Ueda H: Switching of bradykinin-mediated nociception following partial sciatic nerve injury in mice. J Pharmacol Exp Ther 2004, 308: 1158–1164. 10.1124/jpet.103.060335
Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J: siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004, 32: e49. 10.1093/nar/gnh044
Ueda H, Matsunaga S, Inoue M, Yamamoto Y, Hazato T: Complete inhibition of purinoceptor agonist-induced nociception by spinorphin, but not by morphine. Peptides 2000, 21: 1215–1221. 10.1016/S0196-9781(00)00262-X
Jancso G, Kiraly E, Jancso-Gabor A: Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 1977, 270: 741–743. 10.1038/270741a0
Hiura A, Ishizuka H: Changes in features of degenerating primary sensory neurons with time after capsaicin treatment. Acta Neuropathol (Berl) 1989, 78(1):35–46. 10.1007/BF00687400
Inoue M, Shimohira I, Yoshida A, Zimmer A, Takeshima H, Sakurada T, Ueda H: Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. J Pharmacol Exp Ther 1999, 291: 308–313.
Snider WD, McMahon SB: Tackling pain at the source: new ideas about nociceptors. Neuron 1998, 20: 629–632. 10.1016/S0896-6273(00)81003-X
Vulchanova L, Riedl MS, Shuster SJ, Stone LS, Hargreaves KM, Buell G, Surprenant A, North RA, Elde R: P2X3 is expressed by DRG neurons that terminate in inner lamina II. Eur J Neurosci 1998, 10: 3470–3478. 10.1046/j.1460-9568.1998.00355.x
Seltzer Z, Dubner R, Shir Y: A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43: 205–218. 10.1016/0304-3959(90)91074-S
Kim CH, Oh Y, Chung JM, Chung K: The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res Mol Brain Res 2001, 95: 153–161. 10.1016/S0169-328X(01)00226-1
Rashid MH, Inoue M, Kondo S, Kawashima T, Bakoshi S, Ueda H: Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther 2003, 304: 940–948. 10.1124/jpet.102.046250
Zhang Q, Shi TJ, Ji RR, Zhang YZ, Sundler F, Hannibal J, Fahrenkrug J, Hokfelt T: Expression of pituitary adenylate cyclase-activating polypeptide in dorsal root ganglia following axotomy: time course and coexistence. Brain Res 1995, 705: 149–158. 10.1016/0006-8993(95)01150-1
Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, Minami T, Baba A, Ito S: Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 2004, 24: 7283–7291. 10.1523/JNEUROSCI.0983-04.2004
Ruscheweyh R, Forsthuber L, Schoffnegger D, Sandkuhler J: Modification of classical neurochemical markers in identified primary afferent neurons with Abeta-, Adelta-, and C-fibers after chronic constriction injury in mice. J Comp Neurol 2007, 502: 325–336. 10.1002/cne.21311
Landry M, Holmberg K, Zhang X, Hokfelt T: Effect of axotomy on expression of NPY, galanin, and NPY Y1 and Y2 receptors in dorsal root ganglia and the superior cervical ganglion studied with double-labeling in situ hybridization and immunohistochemistry. Exp Neurol 2000, 162: 361–384. 10.1006/exnr.1999.7329
Shi TJ, Zhang X, Berge OG, Erickson JC, Palmiter RD, Hokfelt T: Effect of peripheral axotomy on dorsal root ganglion neuron phenotype and autonomy behaviour in neuropeptide Y-deficient mice. Regul Pept 1998, 75–76: 161–173. 10.1016/S0167-0115(98)00064-0
Naveilhan P, Hassani H, Lucas G, Blakeman KH, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Thoren P, Ernfors P: Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 2001, 409: 513–517. 10.1038/35054063
Intondi AB, Dahlgren MN, Eilers MA, Taylor BK: Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain. Pain 2007.
Hygge-Blakeman K, Brumovsky P, Hao JX, Xu XJ, Hokfelt T, Crawley JN, Wiesenfeld-Hallin Z: Galanin over-expression decreases the development of neuropathic pain-like behaviors in mice after partial sciatic nerve injury. Brain Res 2004, 1025: 152–158. 10.1016/j.brainres.2004.07.078
Blakeman KH, Hao JX, Xu XJ, Jacoby AS, Shine J, Crawley JN, Iismaa T, Wiesenfeld-Hallin Z: Hyperalgesia and increased neuropathic pain-like response in mice lacking galanin receptor 1 receptors. Neuroscience 2003, 117: 221–227. 10.1016/S0306-4522(02)00779-0
Inoue M, Yamaguchi A, Kawakami M, Chun J, Ueda H: Loss of spinal substance P pain transmission under the condition of LPA1 receptor-mediated neuropathic pain. Mol Pain 2006, 2: 25. 10.1186/1744-8069-2-25
Sleeper AA, Cummins TR, Dib-Hajj SD, Hormuzdiar W, Tyrrell L, Waxman SG, Black JA: Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J Neurosci 2000, 20: 7279–7289.
Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R, Black JA, Waxman SG: Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83: 591–600. 10.1016/S0304-3959(99)00169-4
Matsumoto M, Inoue M, Hald A, Yamaguchi A, Ueda H: Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol Pain 2006, 2: 16. 10.1186/1744-8069-2-16
Katims JJ: Neuroselective current perception threshold quantitative sensory test. Muscle Nerve 1997, 20: 1468–1469. 10.1002/(SICI)1097-4598(199711)20:11<1468::AID-MUS21>3.0.CO;2-X
Lengyel C, Torok T, Varkonyi T, Kempler P, Rudas L: Baroreflex sensitivity and heart-rate variability in insulin-dependent diabetics with polyneuropathy. Lancet 1998, 351: 1436–1437. 10.1016/S0140-6736(05)79485-X
Koga K, Furue H, Rashid MH, Takaki A, Katafuchi T, Yoshimura M: Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. Mol Pain 2005, 1: 13. 10.1186/1744-8069-1-13
Cummins TR, Sheets PL, Waxman SG: The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 2007, 131: 243–257. 10.1016/j.pain.2007.07.026
Rush AM, Cummins TR, Waxman SG: Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons. J Physiol 2007, 579: 1–14. 10.1113/jphysiol.2006.121483
Ma L, Matsumoto M, Inoue M, Ueda H: Evidence for Aβ-fiber-mediated allodynia; Pharmacological switch of spinal synaptic transmission. Society for Neuroscience 2007, Dan Diego, CA 2007., 185(9):
Miller BA, Woolf CJ: Glutamate-mediated slow synaptic currents in neonatal rat deep dorsal horn neurons in vitro. J Neurophysiol 1996, 76: 1465–1476.
Xie W, Matsumoto M, Inoue M, Ueda H: Evidence for Aβ-fiber-mediated allodynia; novel appearance of pERK in spinal dorsal horn. Society for Neuroscience 2007, Dan Diego, CA 2007., 185(6):
Handwerker HO, Anton F, Reeh PW: Discharge patterns of afferent cutaneous nerve fibers from the rat's tail during prolonged noxious mechanical stimulation. Exp Brain Res 1987, 65: 493–504. 10.1007/BF00235972
Koerber HR, Mirnics K, Brown PB, Mendell LM: Central sprouting and functional plasticity of regenerated primary afferents. J Neurosci 1994, 14: 3655–3671.
Woolf CJ, Shortland P, Coggeshall RE: Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992, 355: 75–78. 10.1038/355075a0
Okamoto M, Baba H, Goldstein PA, Higashi H, Shimoji K, Yoshimura M: Functional reorganization of sensory pathways in the rat spinal dorsal horn following peripheral nerve injury. J Physiol 2001, 532: 241–250. 10.1111/j.1469-7793.2001.0241g.x
Malmberg AB, Basbaum AI: Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 1998, 76: 215–222. 10.1016/S0304-3959(98)00045-1
Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG: Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 1999, 96: 12096–12101. 10.1073/pnas.96.21.12096
Pentland B, Donald SM: Pain in the Guillain-Barre syndrome: a clinical review. Pain 1994, 59: 159–164. 10.1016/0304-3959(94)90068-X
Carter GT, Jensen MP, Galer BS, Kraft GH, Crabtree LD, Beardsley RM, Abresch RT, Bird TD: Neuropathic pain in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 1998, 79: 1560–1564. 10.1016/S0003-9993(98)90421-X
Osterberg A, Boivie J, Thuomas KA: Central pain in multiple sclerosis--prevalence and clinical characteristics. Eur J Pain 2005, 9: 531–542. 10.1016/j.ejpain.2004.11.005
Gillespie CS, Sherman DL, Fleetwood-Walker SM, Cottrell DF, Tait S, Garry EM, Wallace VC, Ure J, Griffiths IR, Smith A, Brophy PJ: Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron 2000, 26: 523–531. 10.1016/S0896-6273(00)81184-8
Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH: The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993, 291 ( Pt 3): 677–680.
Schumacher KA, Classen HG, Spath M: Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb Haemost 1979, 42: 631–640.
Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3: 582–591. 10.1038/nrc1143
Ye X, Fukushima N, Kingsbury MA, Chun J: Lysophosphatidic acid in neural signaling. Neuroreport 2002, 13: 2169–2175. 10.1097/00001756-200212030-00002
Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J: Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 2003, 6: 1292–1299. 10.1038/nn1157
Fukushima N, Ye X, Chun J: Neurobiology of lysophosphatidic acid signaling. Neuroscientist 2002, 8: 540–550. 10.1177/1073858402238513
Ishii I, Fukushima N, Ye X, Chun J: Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004, 73: 321–354. 10.1146/annurev.biochem.73.011303.073731
Meyer zu Heringdorf D, Jakobs KH: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007, 1768: 923–940. 10.1016/j.bbamem.2006.09.026
Renback K, Inoue M, Yoshida A, Nyberg F, Ueda H: Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res Mol Brain Res 2000, 75: 350–354. 10.1016/S0169-328X(99)00333-2
Renback K, Inoue M, Ueda H: Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci Lett 1999, 270: 59–61. 10.1016/S0304-3940(99)00464-4
Yoshida A, Ueda H: Neurobiology of the Edg2 lysophosphatidic acid receptor. Jpn J Pharmacol 2001, 87: 104–109. 10.1254/jjp.87.104
Ye X, Inoue M, Ueda H: Botulinum toxin C3 inhibits hyperalgesia in mice with partial sciatic nerve injury. Jpn J Pharmacol 2000, 83: 161–163. 10.1254/jjp.83.161
Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389: 990–994. 10.1038/40187
Weiner JA, Chun J: Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci U S A 1999, 96: 5233–5238. 10.1073/pnas.96.9.5233
Mueller BK, Mack H, Teusch N: Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005, 4: 387–398. 10.1038/nrd1719
Yuan J, Slice LW, Gu J, Rozengurt E: Cooperation of Gq, Gi, and G12/13 in protein kinase D activation and phosphorylation induced by lysophosphatidic acid. J Biol Chem 2003, 278: 4882–4891. 10.1074/jbc.M211175200
Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10: 712–718. 10.1038/nm1060
Fujita R, Kiguchi N, Ueda H: LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 2007, 50: 351–355. 10.1016/j.neuint.2006.09.003
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158: 227–233. 10.1083/jcb.200204026
Xing M, Tao L, Insel PA: Role of extracellular signal-regulated kinase and PKC alpha in cytosolic PLA2 activation by bradykinin in MDCK-D1 cells. Am J Physiol 1997, 272: C1380–7.
Hirabayashi T, Murayama T, Shimizu T: Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull 2004, 27: 1168–1173. 10.1248/bpb.27.1168
Durstin M, Durstin S, Molski TF, Becker EL, Sha'afi RI: Cytoplasmic phospholipase A2 translocates to membrane fraction in human neutrophils activated by stimuli that phosphorylate mitogen-activated protein kinase. Proc Natl Acad Sci U S A 1994, 91: 3142–3146. 10.1073/pnas.91.8.3142
Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, Bolotina VM: A novel mechanism for the store-operated calcium influx pathway. Nat Cell Biol 2004, 6: 113–120. 10.1038/ncb1089
Csutora P, Zarayskiy V, Peter K, Monje F, Smani T, Zakharov SI, Litvinov D, Bolotina VM: Activation mechanism for CRAC current and store-operated Ca2+ entry: calcium influx factor and Ca2+-independent phospholipase A2beta-mediated pathway. J Biol Chem 2006, 281: 34926–34935. 10.1074/jbc.M606504200
Inoue M, Ma L, Aoki J, Chun J, Ueda H: Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA),mediates the induction of nerve-injured neuropathic pain. Mol Pain 2008.
Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H: Lysophosphatidylcholine induces neuropathic pain through anaction of autotaxin to generate lysophosphatidic acid. Neuroscience 2008, 152(2):296–8. 10.1016/j.neuroscience.2007.12.041
Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18: 166–175. 10.1016/j.nbd.2004.09.019
Jeffery ND, Blakemore WF: Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 1995, 24: 775–781. 10.1007/BF01191213
Ousman SS, David S: MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J Neurosci 2001, 21: 4649–4656.
Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im DS, Nochi H, Tamoto K, Tomura H, Okajima F: Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003, 64: 994–1005. 10.1124/mol.64.4.994
Zhou XF, Li HY: Roles of glial p75NTR in axonal regeneration. J Neurosci Res 2007, 85: 1601–1605. 10.1002/jnr.21220
Venkatesh K, Chivatakarn O, Sheu SS, Giger RJ: Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J Cell Biol 2007, 177: 393–399. 10.1083/jcb.200702102
Hsieh SH, Ferraro GB, Fournier AE: Myelin-associated inhibitors regulate cofilin phosphorylation and neuronal inhibition through LIM kinase and Slingshot phosphatase. J Neurosci 2006, 26: 1006–1015. 10.1523/JNEUROSCI.2806-05.2006
Devor M: Pesponse of nerves to injury in relation to neuropathic pain. In Wall and Melzack's Textbook of Pain. 5th edition. Edited by: McMahon SB and Koltzenburg M. Philadelphia, Elsevier; 2006:905–927.
Ro LS, Chen ST, Tang LM, Chang HS: Local application of anti-NGF blocks the collateral sprouting in rats following chronic constriction injury of the sciatic nerve. Neurosci Lett 1996, 218: 87–90. 10.1016/S0304-3940(96)13109-8
I thank Makoto Inoue, Ryousuke Fujita, and Misaki Matsumoto for kind help in preparing this manuscript. This study was supported by Special Coordination Funds of the Science and Technology Agency of the Japanese Government and Grant-in-Aid from the Ministry of Education, Science, Culture and Sports of Japan and Human Frontier Science Program.